SequelSEC

Opus Genetics, Inc. IRD

Pharmaceutical Preparations · CIK 0001228627 · Fiscal year ends 1231

Revenue
$9.86M
Fiscal year ended 2026-06-30
Operating income
-$50.61M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$45.90MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.65Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue3.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth29.1%69th
Current ratio6.43x67th
Net margin-349.3%41th
Operating margin-271.9%47th
SBC / revenue23.9%50th

Opus Genetics, Inc. (IRD) reported revenue of $9.86M and net income of -$107.61M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Opus Genetics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Opus Genetics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$9.86M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$50.61M
Net income-$107.61M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$107.61M
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$21.84M
Selling & marketingUnavailable

Balance

Opus Genetics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$88.81M
Total assets$92.97M
Current assets$92.70M
Total liabilities$105.95M
Current liabilities$7.60M
Total equity incl. NCI-$12.99M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$1.04M
GoodwillUnavailable
Long-term debt$35.28M
Accounts payable$1.88M

Cash flow

Opus Genetics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$40.67M
Capital expendituresUnavailable
Investing cash flow$0
Financing cash flow$97.15M
Net change in cashUnavailable
Stock-based compensation$4.46M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Opus Genetics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-513.5%
FCF marginUnavailable
SBC / revenue45.3%
Current ratio12.19x
Revenue YoY growth-36.1%
Net margin-1091.8%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IRD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.